Horizon Therapeutics plc (NASDAQ: HZNP) and
Viela Bio, Inc. (NASDAQ: VIE) have entered into a definitive agreement where Horizon will acquire all issues and outstanding shares of Vielo Bio common stock for USD 53 per share in cash or a fully diluted equity value of USD 3.05 Billion. The transaction is expected to close by the end of the first quarter of 2021. “This acquisition represents a significant step forward in advancing our strategy – to expand our pipeline in order to accelerate our growth over the long term,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Adding Viela’s research and clinical development capabilities along with its deep, mid-stage biologics pipeline to our seasoned R&D and commercial teams, advances our transformation to an innovation-driven biotech company where we will build on the success of TEPEZZA and KRYSTEXXA to bolster our long-term growth trajectory. We intend to maximize the full potential of Viela’s
Israel: Energean announces Karish North Final Investment Decision and new term loan
14 Jan 2021
Final Investment Decision ( FID ) on the
Karish North gas development, offshore Israel, 21-months after the announcement of the discovery.
In November 2020, DeGolyer and MacNaughton issued an independent Competent Persons Report that, inter alia, certified 2P reserves of 32 Bcm of gas plus 34 million barrels of liquids (approx. 241 million barrels of oil equivalent in aggregate) in Karish North as at 30 June 2020. The discovery will be commercialised via a low-cost tie-back to the Energean Power FPSO, which will be just 5.4km away. Production from the first well at Karish North is expected to be up to 300 mmscf/d (approx. 3 Bcm/yr) and first production is expected during 2H 2023. Initial capital expenditure in the project is expected to be approx. $150 million, or $0.6/boe; and Energean estimates that the project will deliver IRRs inexcess of 40%.
Scripps Completes Acquisition Of Ion Media tvnewscheck.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tvnewscheck.com Daily Mail and Mail on Sunday newspapers.
Charles Pretzlik / Jonathan Glass + 44 (0)20 7404 5959
Andrew Seaton / Robert Way / William Morton + 44 (0) 20 7986 4000
Edmund Byers / Celia Murray / Richard Walsh + 44 (0) 20 7742 4000
Mark Sorrell / Jose Barreto + 44 (0) 20 7774 1000
William Rucker / Nicholas Page + 44 (0) 20 7187 2000 Cleary Gottlieb Steen & Hamilton LLP, Freshfields Bruckhaus Deringer LLP and Kirkland & Ellis LLP are retained as legal advisers to Allied Universal and Allied Bidco. Linklaters LLP is retained as legal adviser to G4S. Important Notices Capitalised terms used in this section (Important Notices) but not defined in this announcement have the meanings given to them in the Firm Offer Announcement. Important notices relating to financial advisers Morgan Stanley & Co. International plc ( Morgan Stanley ) which is authorised by the Prudential Regulation Authority ( PRA
Sabre Corporation Announces Refinancing of Term A Loans and Redemption of Senior Secured Notes
News provided by
Share this article
Share this article
SOUTHLAKE, Texas, Dec. 17, 2020 /PRNewswire/ Sabre Corporation ( Sabre ) (Nasdaq: SABR) today announced a refinancing of a portion of its existing indebtedness, including the repayment in full of its Term Loan A credit facility and the satisfaction and discharge of Sabre GLBL Inc. s 5.250% Senior Secured Notes due November 2023 (the November 2023 Notes ). Sabre incurred no additional indebtedness as a result of the refinancing above the refinanced amount, other than amounts covering certain interest, fees and expenses. The refinancing has meaningfully improved Sabre s debt maturity profile and preserves its flexibility.